Shares of Summit Therapeutics Inc. (SMMT) declined 11% on Monday morning despite reporting positive overall survival results from the Phase III HARMONi-6 trial evaluating ivonescimab in first-line treatment of advanced squamous non-small cell lung cancer.
The stock is currently trading at $15.62 on Nasdaq, down $1.92, or 10.95%. It opened at $16.69 after closing the previous session at $17.54. The stock has traded between $13.83 and $30.98 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.